E2XE34 logo

Exelixis, Inc.BOVESPA:E2XE34 Stock Report

Market Cap R$72.6b
Share Price
n/a
1Yn/a
7D0%
1D-1.6%
Portfolio Value
​
View

Exelixis, Inc.

BOVESPA:E2XE34 Stock Report

Market Cap: R$72.6b

Exelixis (E2XE34) Stock Overview

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details

E2XE34 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 65.2% below our estimate of its fair value

Earnings grew by 29.5% over the past year

Risk Analysis

Shares are highly illiquid


E2XE34 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW495,827 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
495,827 investors already sharing narratives
View all narratives

Exelixis, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Exelixis
Historical stock prices
Current Share PriceUS$134.42
52 Week HighUS$136.55
52 Week LowUS$98.24
Beta0.42
1 Month Change9.92%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO177.58%

Recent News & Updates

Recent updates

Shareholder Returns

E2XE34BR BiotechsBR Market
7D0%5.9%0.3%
1Yn/a26.2%10.9%

Return vs Industry: Insufficient data to determine how E2XE34 performed against the BR Biotechs industry.

Return vs Market: Insufficient data to determine how E2XE34 performed against the BR Market.

Price Volatility

Is E2XE34's price volatile compared to industry and market?
E2XE34 volatility
E2XE34 Average Weekly Movementn/a
Biotechs Industry Average Movement9.4%
Market Average Movement4.6%
10% most volatile stocks in BR Market7.9%
10% least volatile stocks in BR Market1.9%

Stable Share Price: E2XE34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine E2XE34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19941,077Mike Morrisseywww.exelixis.com

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

Exelixis, Inc. Fundamentals Summary

How do Exelixis's earnings and revenue compare to its market cap?
E2XE34 fundamental statistics
Market capR$72.61b
Earnings (TTM)R$4.31b
Revenue (TTM)R$12.29b
16.8x
P/E Ratio
5.9x
P/S Ratio

Is E2XE34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
E2XE34 income statement (TTM)
RevenueUS$2.38b
Cost of RevenueUS$84.48m
Gross ProfitUS$2.29b
Other ExpensesUS$1.46b
EarningsUS$833.42m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)3.32
Gross Margin96.44%
Net Profit Margin35.08%
Debt/Equity Ratio0%

How did E2XE34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/05 18:50
End of Day Share Price 2026/06/23 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exelixis, Inc. is covered by 41 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Peter LawsonBarclays
Jason Matthew GerberryBofA Global Research